Login / Signup

Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies.

Joao GorgulhoChristoph RoderburgFabian BeierCarsten BokemeyerTim Henrik BrümmendorfSven H LoosenTom Luedde
Published in: British journal of cancer (2024)
Pending prospective validation, sLAG3 and correlating circulating T-cell subsets can be used as a non-invasive predictive marker to predict outcome to ICI therapy to help identifying ideal ICI candidates in the future.
Keyphrases
  • patients undergoing
  • peripheral blood
  • current status
  • genome wide
  • stem cells
  • gene expression
  • genome wide identification
  • dna methylation